Investigational New Drugs

, Volume 28, Issue 5, pp 684–689 | Cite as

Oral metronomic cyclophosphamide in elderly with metastatic melanoma

  • Estelle Borne
  • Eve Desmedt
  • Alain Duhamel
  • Xavier Mirabel
  • Véronique Dziwniel
  • Cyril Maire
  • Valérie Florin
  • Véronique Martinot
  • Nicolas Penel
  • Sophie Vercambre-Darras
  • Laurent MortierEmail author


Introduction In Western countries, the number of frail elderly people with metastatic melanoma (MM) keeps increasing. Conventional chemotherapy frequently induces imbalance in frail physiological cases. We propose to treat these patients with oral metronomic cyclophosphamide. Patients and methods This retrospective study analyses the data of patients with unresectable MM who received 50 to 100 mg of cyclophosphamide a day, 3 weeks out of 4. Main evaluation criterion was safety. Secondary evaluation criteria were objective response rate and overall survival. Results Thirteen patients were included (median age: 80, 5 AJCC stage III and 8 AJCC stage IV). Clinical and biological safety were good, leading to long home staying and rare treatment discontinuations. Main toxicity observed was lymphopenia; no opportunist infection occurred. The control rate was 46%: one partial response and five stable diseases (median: 10 months). Survival after beginning of treatment ranged from 4 to 37 months (median: 8 months). Discussion Literature about MM in frail elderly is limited. Still, specific treatment is necessary. Cyclophosphamide in metronomic schema was well tolerated. The response rate was difficult to assess (small population) but several patients presented with long lasting stabilisation. The mechanisms of action of this treatment are original, associating antiangiogenic action and immunomodulation. Conclusion Cyclophosphamide in metronomic schema showed good safety results for this frail population. Oral treatment enabled patients to stay at home longer and limited hospitalisation time. A larger controlled study will be necessary to confirm these encouraging results in elderly with MM, a classical chemoresistant tumor.


Metastatic melanoma Frail elderly Cyclophosphamide Metronomic schedule 


  1. 1.
    Chérié-Challine L, Halna J-M, Remontet L (2004) Situation épidémiologique du mélanome cutané en France et impact en termes de prévention. Bull Epidémiol Hebd 2:5–8Google Scholar
  2. 2.
    Nashan D, Müller M, Grabbe S, Wustlich S, Enk A (2007) Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 21:1305–1318CrossRefPubMedGoogle Scholar
  3. 3.
    Sasse A, Sasse E, Clark L, Ulloa L, Clark O (2008) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma (review). Cochrane Database Syst Rev 24:CD005413Google Scholar
  4. 4.
    Balch C, Murray D, Presant C, Bartolucci A (1984) Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 95:454–459PubMedGoogle Scholar
  5. 5.
    Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73–80CrossRefPubMedGoogle Scholar
  6. 6.
    Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16:1243–1252CrossRefPubMedGoogle Scholar
  7. 7.
    Lord R, Nair S, Schache A, Spicer J, Somailhah N, Khoo V, Pandha H (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostatic cancer: a phase II study. J Urol 177:2136–2140CrossRefPubMedGoogle Scholar
  8. 8.
    Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS (2004) A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994–4000CrossRefPubMedGoogle Scholar
  9. 9.
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood J, McMasters K, Mihm MF, Morton D, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648PubMedGoogle Scholar
  10. 10.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, ATv O, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  11. 11.
    Homsi J, Kashani-Sabet M, Messina JL, Daud A (2005) Cutaneous melanoma: prognostic factors. Cancer Control 12:223–229PubMedGoogle Scholar
  12. 12.
    Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier A, Guizard A, Tretarre B, Launoy G, Colonna M, Danzon A, Molinie F, Troussard X, Bourdon-Raverdy N, Carli P, Jaffré A, Bessaguet C, Sauleau E, Schvartz C, Arveux P, Maynadié M, Grosclaude P, Estève J, Faivre J (2007) Survival of cancer patients in France: a population-based study from the association of the french cancer registries (FRANCIM). Eur J Cancer 43:149–160CrossRefPubMedGoogle Scholar
  13. 13.
    Balducci L (2007) Aging, frailty and chemotherapy. Cancer Control 14:7–12PubMedGoogle Scholar
  14. 14.
    Extermann M (2007) Interaction between comorbidity and cancer. Cancer Control 14:13–22PubMedGoogle Scholar
  15. 15.
    Carriere I, Dupuy A, Lacroux A, Cristol J, Delcourt C, Pathologies Liées à l’Age Study Group (2008) Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. J Am Geriatr Soc 56:840–846CrossRefGoogle Scholar
  16. 16.
    Satariano W, Ragland D (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104–110PubMedGoogle Scholar
  17. 17.
    Freyer G, Geay J, Touzet S, Provencal J, Weber B, Jacquin J, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16:1795–1800CrossRefPubMedGoogle Scholar
  18. 18.
    Kumar A, Soares HP, Balducci L, Djulbegovic B (2007) Treatment tolerance and efficacy in geriatric oncology : a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 25:1272–1276CrossRefPubMedGoogle Scholar
  19. 19.
    Hutchins L, Unger J, Crowley J (1999) Underrepresentation of patients 65 years of age and older in cancer treatment trials. N Engl J Med 341:2061–2067CrossRefPubMedGoogle Scholar
  20. 20.
    Gogas H, Kirkwood J, Sondak V (2007) Chemotherapy for metastatic melanoma: time for a change? Cancer 109:455–464CrossRefPubMedGoogle Scholar
  21. 21.
    Cashin R, Lui P, Machado M, Hemels M, Corey-Lisle P, Einarson T (2008) Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life-studies. Value Health 11:259–271CrossRefPubMedGoogle Scholar
  22. 22.
    Avril M-F, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Porta VG, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Larriba JLG, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125CrossRefPubMedGoogle Scholar
  23. 23.
    Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMedGoogle Scholar
  24. 24.
    Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65:87–92PubMedGoogle Scholar
  25. 25.
    Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMedGoogle Scholar
  26. 26.
    Mahabeleshwar G, Byzoya T (2007) Angiogenesis in melanoma. Semin Oncol 34:555–565CrossRefPubMedGoogle Scholar
  27. 27.
    Hellwig SM, Damen CA, Adrichem NP, Blijham GH, Groenewegen G, Griffioen AW (1997) Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett 120:203–211CrossRefPubMedGoogle Scholar
  28. 28.
    Dirkx AEM, MGAo E, Castermans K, DWJvd S, Thijssen VLJL, Dings RPM, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JCA, Griffioen AW (2006) Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 20:621–630CrossRefPubMedGoogle Scholar
  29. 29.
    Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G (1996) Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancy: role of angiogenic factors. Cancer Res 56:1111–1117PubMedGoogle Scholar
  30. 30.
    Conforti A, Ollila D, Kelley M, Gammon G, Morton D (1997) Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 66:55–64CrossRefPubMedGoogle Scholar
  31. 31.
    Salem M, Kadima A, El-Naggar S, Rubinstein M, Chen Y, Gillanders W, Cole D (1997) Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30:40–53CrossRefGoogle Scholar
  32. 32.
    Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels J-PH, Bieler J, Emens L, Reilly R, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591–1602CrossRefPubMedGoogle Scholar
  33. 33.
    Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E (2007) Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13:644–653CrossRefPubMedGoogle Scholar
  34. 34.
    Tarhini A, Agarwala S (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19:19–25CrossRefPubMedGoogle Scholar
  35. 35.
    Balducci L (2006) Management of cancer in the elderly. Oncology (Williston Park) 20:135–143Google Scholar
  36. 36.
    Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346PubMedGoogle Scholar
  37. 37.
    Griffith K, Read E, Carrasquillo J, Carter C, Yang J, Fischer B, Aebersold P, Packard B, Yu M, Rosenberg S (1989) In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81:1709–1717CrossRefPubMedGoogle Scholar
  38. 38.
    Matar P, Rozados VR, Gervasoni SI, Scharovsky GO (2002) Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588–596CrossRefPubMedGoogle Scholar
  39. 39.
    Tatsumi T, Kierstead L, Ranieri E, Gesualdo L, Schena F, Finke J, Bukowski R, Mueller-Berghaus J, Kirkwood J, Kwok W, Storkus W (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619–628CrossRefPubMedGoogle Scholar
  40. 40.
    Lutsiak C, Semnani RT, Pascalis RD, Kashmiri SVS, Scholm J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868CrossRefPubMedGoogle Scholar
  41. 41.
    Ben-Efraim S (2001) Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targets 2:197–212CrossRefPubMedGoogle Scholar
  42. 42.
    Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Cesne AL, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648CrossRefPubMedGoogle Scholar
  43. 43.
    Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49:1649–1654PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Estelle Borne
    • 1
  • Eve Desmedt
    • 1
  • Alain Duhamel
    • 2
  • Xavier Mirabel
    • 3
  • Véronique Dziwniel
    • 4
  • Cyril Maire
    • 1
  • Valérie Florin
    • 1
  • Véronique Martinot
    • 5
  • Nicolas Penel
    • 6
  • Sophie Vercambre-Darras
    • 1
  • Laurent Mortier
    • 1
    • 7
    Email author
  1. 1.Clinique de Dermatologie, Centre Hospitalier Régional et UniversitaireUniversité Lille 2LilleFrance
  2. 2.Département de BiostatistiquesUniversité Lille 2LilleFrance
  3. 3.Département de RadiothérapieCentre Oscar LambretLilleFrance
  4. 4.Department of Modern LanguagesEcole Centrale de LilleVilleneuve d’AscqFrance
  5. 5.Département de Chirurgie PlastiqueCentre Hospitalier Régional et UniversitaireLilleFrance
  6. 6.Département de Cancérologie GénéraleCentre Oscar LambretLilleFrance
  7. 7.Clinique de DermatologieHôpital Claude HuriezLille cedexFrance

Personalised recommendations